> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Amneal Swings To $22 Million Quarterly Loss On Kashiv Costs, Yet Lifts Its 2026 Outlook
- URL: https://www.bullished.co/amneal-swings-to-22-million-quarterly-loss-on-kashiv-costs-yet-lifts-its-2026-outlook-cc5543d7/
- Published: 2026-11-03T13:18:14.000Z
- Updated: 2026-11-03T13:18:14.000Z
- Description: Revenue rose 10% to $863 million and adjusted EBITDA hit $207 million, but net debt climbed to $3.07 billion after the Kashiv purchase.
- Author: Matteo Parrino
- Tags: Earnings, AMRX, Industry: Healthcare

Amneal Pharmaceuticals, a drugmaker that sells generics, branded medicines and biosimilars, [lost $22 million](https://www.globenewswire.com/news-release/2026/11/03/3394002/0/en/amneal-reports-third-quarter-2026-financial-results.html?ref=bullished.co) attributable to the company in the third quarter, as costs tied to buying Kashiv BioSciences and a higher tax bill outweighed higher sales. The company still raised its 2026 outlook for revenue and adjusted earnings, and trimmed its operating cash flow forecast, it said Tuesday in an [8-K](https://www.sec.gov/Archives/edgar/data/0001723128/000172312826000035/amrx-20261103.htm?ref=bullished.co).

## A loss beside a stronger adjusted quarter

The loss works out to $0.06 per diluted share, against net income of $2 million a year earlier. Revenue rose 10% to [$863 million](https://www.globenewswire.com/news-release/2026/11/03/3394002/0/en/amneal-reports-third-quarter-2026-financial-results.html?ref=bullished.co) from $785 million. The company said non-recurring acquisition and integration costs and a higher tax provision more than offset higher revenue and gross profit. The larger share count after the Kashiv deal also weighed on per-share results.

On adjusted measures the quarter was stronger. Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and other items the company excludes) rose 30% to $207 million. Adjusted diluted earnings per share rose 53% to $0.26 from $0.17.

Co-CEOs Chirag and Chintu Patel said the Kashiv integration "is proceeding well" and that they see "long-term growth potential in biosimilars."

## Generics and branded drugs grow, AvKARE shrinks

Amneal runs three units: Affordable Medicines (retail generics, injectables and biosimilars), Specialty (branded neurology and endocrine drugs) and AvKARE, which distributes to government, retail and institutional customers.

Affordable Medicines revenue grew 19%, driven by biosimilars, women's health patches and new launches. Specialty grew 20%, led by CREXONT, the BREKIYA autoinjector and UNITHROID. AvKARE fell 17%, as expected, because of a non-recurring cardiovascular product launch in the prior year.

## Higher targets, more debt, less cash flow

For 2026 the company now expects revenue of $3.15 billion to $3.25 billion, up from $3.10 billion to $3.20 billion. Adjusted EBITDA guidance rises to $800 million to $815 million from $750 million to $780 million, and adjusted EPS to $1.04 to $1.08 from $0.96 to $1.06.

Operating cash flow guidance moves down to $325 million to $375 million from $350 million to $400 million. The company attributed the change to working capital, including higher inventory in key growth areas.

Net debt stood at about $3.07 billion on September 30, up from about $2.41 billion at the end of 2025\. Net leverage was 3.9 times adjusted EBITDA, against 3.5 times at year-end. In August the company borrowed an additional $350 million under its term loan to fund part of the Kashiv cash price.

Management discussed the results on a call at 8:30 a.m. ET Tuesday.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Amneal Pharmaceuticals, Inc. (AMRX)](https://www.sec.gov/Archives/edgar/data/0001723128/000172312826000035/amrx-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit amrx-q32026ex991.htm — Amneal Pharmaceuticals, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001723128/000172312826000035/amrx-q32026ex991.htm?ref=bullished.co) — SEC EDGAR
- [Amneal Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/03/3394002/0/en/amneal-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com